Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024

Business Wire04-26

SAN DIEGO, April 25, 2024--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2430252798?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UoUYtvtBJHHw8rrbYU2mhw--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/d93fffe6d2b7167ea35743f2457a876f","is_english":true,"pubTime":"2024-04-26 04:01","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2430252798","market":"us","top_or_hot":-1,"title":"Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024","media":"Business Wire","content":"<div>\n<p>SAN DIEGO, April 25, 2024--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the \"Company\", \"Arcturus\", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of ...</p>\n\n<a href=\"https://finance.yahoo.com/news/arcturus-therapeutics-report-first-quarter-200100867.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-26 04:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/arcturus-therapeutics-report-first-quarter-200100867.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SAN DIEGO, April 25, 2024--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the \"Company\", \"Arcturus\", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of ...</p>\n\n<a href=\"https://finance.yahoo.com/news/arcturus-therapeutics-report-first-quarter-200100867.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-report-first-quarter-200100867.html","article_id":"2430252798","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UoUYtvtBJHHw8rrbYU2mhw--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/d93fffe6d2b7167ea35743f2457a876f"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2430252798","pubTimestamp":1714075260,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"SAN DIEGO, April 25, 2024----Arcturus Therapeutics Holdings Inc. , a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2024 after the market close on Wednesday, May 8 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 8, 2024.Arcturus Therapeutics First Quarter 2024 Earnings Conference Call. IR and Media Contacts Arcturus TherapeuticsNeda SafarzadehVP, Head of IR/PR/MarketingIR@ArcturusRx.com","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4585":"ETF&股票定投概念","BK4588":"碎股","RNA":"Avidity Biosciences, Inc.","BK4505":"高瓴资本持仓","BK4139":"生物科技","ARCT":"Arcturus Therapeutics Ltd."},"translate_title":"Arcturus Therapeutics将于2024年5月8日报告第一季度财务业绩并提供公司最新情况","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"ARCT":0.9,"RNA":0.9},"content_text":"SAN DIEGO, April 25, 2024--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the \"Company\", \"Arcturus\", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2024 after the market close on Wednesday, May 8 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 8, 2024.\nArcturus Therapeutics First Quarter 2024 Earnings Conference Call\n\nWednesday, May 8, 2024 @ 4:30 p.m. ET\nDomestic: 1-888-886-7786\nInternational: 1-416-764-8658\nConference ID: 96934019\nWebcast: Link\n\nAbout Arcturus Therapeutics\nFounded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine (Kostaive®) in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase deficiency and cystic fibrosis, along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240425873170/en/\nContacts\nIR and Media Contacts Arcturus TherapeuticsNeda SafarzadehVP, Head of IR/PR/MarketingIR@ArcturusRx.com","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2430252798"}